Brief: Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025
25/03/2025 12:36
March 25 (Reuters) - Nuvation Bio Inc NUVB.N: NUVATION BIO TO PRESENT MATCHING-ADJUSTED INDIRECT COMPARISON DATA FOR TALETRECTINIB VERSUS. CRIZOTINIB DURING MINI ORAL PRESENTATION AT THE EUROPEAN LUNG CANCER CONGRESS 2025 Source text: ID:nBw8mgcS7a Further company coverage: NUVB.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nuvation Bio
See all newsBrief: Nuvation Bio To Expand Pivotal Phase 3 Sigma Study Of Safusidenib For Idh1-Mutant Glioma To Six European Countries
Brief: Nuvation Bio To Report Third Quarter 2026 Financial Results And Provide Business Update On November 4, 2026
U.S. RESEARCH ROUNDUP-Everpure, Marvell Technology, Okta
Nuvation Bio Inc. reports results for the quarter ended June 30 - Earnings Summary
Nuvation Bio Q2 revenue beats estimates on IBTROZI growth